1-20 of 266 Search Results for

glp

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Book Chapter
Series: Frontiers in Diabetes
Volume: 13
Published: 27 May 1997
10.1159/000194730
EISBN: 978-3-318-01934-6
Book Chapter
Book Chapter
Series: Frontiers in Diabetes
Volume: 13
Published: 27 May 1997
10.1159/000194734
EISBN: 978-3-318-01934-6
Book Chapter
Series: Frontiers in Diabetes
Volume: 13
Published: 27 May 1997
10.1159/000194741
EISBN: 978-3-318-01934-6
Book Chapter
Book Chapter
Series: Frontiers in Diabetes
Volume: 13
Published: 27 May 1997
10.1159/000194738
EISBN: 978-3-318-01934-6
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475730
EISBN: 978-3-318-05974-8
... secretion, in response to oral glucose uptake, as compared to intravenous glucose infusion has further been termed the “incretin effect.” As a prototype incretin hormone, the biology of glucagon-like peptide 1 (GLP-1) has been intensively studied. GLP-1 actions are mediated through cyclic adenosine...
Book Chapter
Series: Frontiers in Diabetes
Volume: 21
Published: 16 February 2012
10.1159/000334509
EISBN: 978-3-8055-9944-3
... Abstract Incretin hormones play a key role in the regulation of postprandial insulin release. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) account for approximately 90% of the incretin effect, but only GLP-1 has been shown to play a role in the control...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 43
Published: 12 June 2014
10.1159/000360598
EISBN: 978-3-318-02674-0
.... In this chapter, we will discuss the potential mechanisms and current understanding of CV and CBV benefits of native glucagon-like peptide (GLP)-1, GLP-1 receptor agonists and analogues, and of dipeptidyl peptidase-4 inhibitor therapies as a means to better understand differences in safety and efficacy...
Book Chapter
Series: Frontiers in Diabetes
Volume: 29
Published: 31 August 2020
10.1159/000506555
EISBN: 978-3-318-06734-7
... plays a leading role in the pathophysiology of all forms of diabetes. Furthermore, glucagon belongs to a large family of peptides, all derived from the same precursor. Out of these, two glucagon-like peptides (GLPs), named GLP-1 and GLP-2, are now recognized as major players in physiology...
Book Chapter
Series: Endocrine Development
Volume: 31
Published: 27 January 2016
10.1159/000439372
EISBN: 978-3-318-05639-6
... Abstract This chapter deals with novel therapeutic approaches, predominantly for type 2 diabetes. Incretin-based therapies utilize the effects of glucagon-like peptide-1 (GLP-1), which stimulates insulin and inhibits glucagon secretion in a glucose-dependent manner. Incretin-based therapies...
Book Chapter
Series: Endocrine Development
Volume: 30
Published: 10 December 2015
10.1159/000439323
EISBN: 978-3-318-05637-2
... among adults. Among these, glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment appears to have reasonable weight loss efficacy along with other beneficial pleiotropic effects. Although larger trials will be required to confirm the results, two small pediatric clinical trials have suggested...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475731
EISBN: 978-3-318-05974-8
... peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), referred to as incretins, have gained enormous attention due to their insulinotropic action and relevance in the treatment of type 2 diabetes (T2D) [ 4 ]. Especially, GLP-1 and GLP-1-based antidiabetic therapies are in the spotlight...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475737
EISBN: 978-3-318-05974-8
..., molecularly crafted unimolecular “multi-agonism” of balanced activity at 3 key receptors involved in metabolism and specifically the glucagon-like peptide (GLP)-1 receptor, glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon receptor was reported as superior to conventional monoagonist...
Book
Book Cover Image
Series: Frontiers in Diabetes
Volume: 13
Published: 27 May 1997
10.1159/isbn.978-3-318-01934-6
EISBN: 978-3-318-01934-6
Book Chapter
Series: Frontiers in Diabetes
Volume: 19
Published: 12 August 2008
10.1159/000152023
EISBN: 978-3-8055-8641-2
... Abstract Recently we have discovered that the incretin hormone glucagon-like peptide-1 (GLP-2) is an important mediator of cell migration and that GLP-2 is also able to increase proliferation of colon cancer cells. We found that dipeptidyl peptidase IV inhibitors - thought to be a treatment...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475734
EISBN: 978-3-318-05974-8
... intake by inducing meal termination [ 18 ]. Intestinal L cells, located in ileum and large intestine, co-secrete peptide YY (PYY), glucagon-like-peptide-1 (GLP-1), and oxyntomodulin [ 19 , 20 , 21 ], while the pancreas co-secretes amylin together with insulin from β-cells, as well as pancreatic...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 42
Published: 10 April 2014
10.1159/000358321
EISBN: 978-3-318-02639-9
.... The gut epithelial machinery includes neuroactive peptides like glucagon-like peptide-1 (GLP-1), peptide tyrosine-tyrosine (PYY) and cholecystokinin (CCK), which are secreted upon specific nutrient stimulation. G protein-coupled receptors (GPCRs) and solute transporters expressed on the apical end...
Book
Book Cover Image
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/isbn.978-3-318-05974-8
EISBN: 978-3-318-05974-8